Bristol Myers Squibb Company $BMY Shares Bought by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. boosted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 4,986.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 268,942 shares of the biopharmaceutical company’s stock after acquiring an additional 263,655 shares during the period. Rakuten Investment Management Inc.’s holdings in Bristol Myers Squibb were worth $14,552,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. waypoint wealth counsel purchased a new stake in shares of Bristol Myers Squibb during the 4th quarter worth approximately $1,194,000. Life Cycle Investment Partners Ltd purchased a new stake in shares of Bristol Myers Squibb during the 4th quarter worth approximately $34,406,000. Axxcess Wealth Management LLC lifted its position in shares of Bristol Myers Squibb by 27.4% during the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock worth $5,322,000 after buying an additional 21,196 shares during the last quarter. M&G PLC lifted its position in shares of Bristol Myers Squibb by 1.4% during the 3rd quarter. M&G PLC now owns 6,885,188 shares of the biopharmaceutical company’s stock worth $309,833,000 after buying an additional 97,063 shares during the last quarter. Finally, Daytona Street Capital LLC purchased a new stake in shares of Bristol Myers Squibb during the 4th quarter worth approximately $1,362,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

BMY has been the subject of several recent analyst reports. Royal Bank Of Canada initiated coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price objective for the company. Wall Street Zen downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Piper Sandler reiterated an “overweight” rating and issued a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Finally, Guggenheim reiterated a “buy” rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $61.31.

Bristol Myers Squibb Stock Down 1.4%

BMY stock opened at $56.30 on Tuesday. The company has a fifty day moving average price of $57.67 and a 200 day moving average price of $56.99. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89. The company has a market cap of $114.97 billion, a price-to-earnings ratio of 15.82, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. The firm had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. Bristol Myers Squibb’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.